US 12,280,119 B2
Chimeric transmembrane proteins and uses thereof
Peter Emtage, Lafayette, CA (US); and Rosa Vincent, New York City, NY (US)
Assigned to KITE PHARMA, INC., Foster City, CA (US)
Appl. No. 17/040,009
Filed by KITE PHARMA, INC., Santa Monica, CA (US)
PCT Filed Mar. 21, 2019, PCT No. PCT/US2019/023424
§ 371(c)(1), (2) Date Sep. 21, 2020,
PCT Pub. No. WO2019/183389, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/647,498, filed on Mar. 23, 2018.
Prior Publication US 2021/0015864 A1, Jan. 21, 2021
Int. Cl. A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 47/62 (2017.01); A61K 47/65 (2017.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01)
CPC A61K 47/65 (2017.08) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); C07K 14/55 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/7155 (2013.01)] 7 Claims
 
1. A chimeric transmembrane protein comprising:
an extracellular IL-2 domain;
an extracellular sushi domain from an alpha chain of interleukin-2 receptor;
a transmembrane domain of an alpha chain of interleukin-2 receptor; and
an intracellular domain capable of signaling.